Platelet-rich Plasma (PRP), Platelet-rich Fibrin (PRF), Periodontal Infrabony Defects


Aim: To compare the clinical outcomes of platelet-derived biomaterials, including recombinant human platelet-derived growth factors receptor BB (rhPDGF-BB), platelet-rich plasma (PRP) and platelet-rich fibrin (PRF), for treatment of periodontal infra-bony defects. Materials and Methods: A meta-analysis was conducted to compare pocket depth reduction (PRD) and clinical attachment gain (CAG) with and without rhPDGF-BB, PRP or PRF, for surgical treatments of periodontal infra-bony pockets. Eligible studies were randomized controlled clinical trials in adults with periodontal infra-bony defects. Results: Thirty-four randomized controlled trials involving 939 patients with a mean follow-up of 9.29(±2.49) months were included in this meta-analysis. All three platelet-derived materials achieved better outcomes in both PDR and CAG (p < 0.00001) in comparison to controls. The effect size of the platelet-derived biomaterials were on average 0.81(95%CI 0.62 to 0.99)mm [(0.96mm for PRF, 0.80mm for rhPDGF-BB and 0.63mm for PRP)] for PDR, and 0.82 (95%CI 0.60 to 1.03)mm [( 0.92mm for PRF, 1.01mm for rhPDGF-BB and 0.60mm for PRP)] for CAG. Conclusions: Periodontal therapies using platelet-derived biomaterials improved PDR and CAG in the short-term, compared to controls without these materials. However, there is not clinically significant PDR and CAG between the platelet materials.